Literature DB >> 31421167

Efficacy of clarithromycin against H5N1 and H7N9 avian influenza a virus infection in cynomolgus monkeys.

Masahiko Arikata1, Yasushi Itoh2, Shintaro Shichinohe3, Misako Nakayama3, Hirohito Ishigaki3, Takaaki Kinoshita3, Mai Quynh Le4, Yoshihiro Kawaoka5, Kazumasa Ogasawara6, Takeshi Shimizu1.   

Abstract

Clarithromycin (CAM), a 14-membered ring macrolide, has anti-inflammatory and immunomodulatory actions and antiviral effects in seasonal influenza virus infection. We examined the prophylactic and therapeutic efficacy of CAM against H5N1 highly pathogenic and H7N9 low pathogenic avian influenza virus infections in cynomolgus monkeys. CAM suppressed H5N1 virus-induced severe signs of disease in the treated monkeys and inhibited virus propagation in tracheal samples and the production of inflammatory cytokines in the lungs of monkeys infected with H5N1 and H7N9 viruses. The prophylactic administration of CAM showed more suppressive effects on clinical signs of disease and viral titers than did therapeutic administration. Thus, since administration of CAM alone showed a tendency to ameliorate clinical sings and to reduce levels of inflammatory cytokines, the macrolides are expected to have effects in combination with the other antiviral drugs on the prophylactic and treatment of patients with severe avian influenza virus infection, which should be further investigated.
Copyright © 2019. Published by Elsevier B.V.

Entities:  

Keywords:  Avian influenza virus; Clarithromycin; Cynomolgus monkey; H5N1; H7N9

Mesh:

Substances:

Year:  2019        PMID: 31421167     DOI: 10.1016/j.antiviral.2019.104591

Source DB:  PubMed          Journal:  Antiviral Res        ISSN: 0166-3542            Impact factor:   5.970


  8 in total

Review 1.  Repurposing of antibiotics for clinical management of COVID-19: a narrative review.

Authors:  Abdourahamane Yacouba; Ahmed Olowo-Okere; Ismaeel Yunusa
Journal:  Ann Clin Microbiol Antimicrob       Date:  2021-05-21       Impact factor: 3.944

Review 2.  Antiviral Activity of Approved Antibacterial, Antifungal, Antiprotozoal and Anthelmintic Drugs: Chances for Drug Repurposing for Antiviral Drug Discovery.

Authors:  Leena Abdulaziz; Esraa Elhadi; Ejlal A Abdallah; Fadlalbaseer A Alnoor; Bashir A Yousef
Journal:  J Exp Pharmacol       Date:  2022-03-08

Review 3.  Influenza antivirals and animal models.

Authors:  C Joaquin Caceres; Brittany Seibert; Flavio Cargnin Faccin; Stivalis Cardenas-Garcia; Daniela S Rajao; Daniel R Perez
Journal:  FEBS Open Bio       Date:  2022-04-27       Impact factor: 2.792

4.  Erythromycin Estolate Is a Potent Inhibitor Against HCoV-OC43 by Directly Inactivating the Virus Particle.

Authors:  Xiaohuan Wang; Yongkang Chen; Huichun Shi; Peng Zou
Journal:  Front Cell Infect Microbiol       Date:  2022-07-07       Impact factor: 6.073

5.  Successful recovery of COVID-19 pneumonia in a patient from Colombia after receiving chloroquine and clarithromycin.

Authors:  José Millán-Oñate; William Millan; Luis Alfonso Mendoza; Carlos Guillermo Sánchez; Hugo Fernandez-Suarez; D Katterine Bonilla-Aldana; Alfonso J Rodríguez-Morales
Journal:  Ann Clin Microbiol Antimicrob       Date:  2020-04-24       Impact factor: 3.944

6.  A novel plan to deal with SARS-CoV-2 and COVID-19 disease.

Authors:  Raphael B Stricker; Melissa C Fesler
Journal:  J Med Virol       Date:  2020-06-02       Impact factor: 20.693

7.  Clinical evidences on the antiviral properties of macrolide antibiotics in the COVID-19 era and beyond.

Authors:  Dimitri Poddighe; Mohamad Aljofan
Journal:  Antivir Chem Chemother       Date:  2020 Jan-Dec

Review 8.  Management of SARS-CoV-2 Infection: Key Focus in Macrolides Efficacy for COVID-19.

Authors:  Gaber El-Saber Batiha; Marwa A Zayed; Aya A Awad; Hazem M Shaheen; Suleiman Mustapha; Oscar Herrera-Calderon; Jorge Pamplona Pagnossa; Abdelazeem M Algammal; Muhammad Zahoor; Achyut Adhikari; Ishan Pandey; Sara T Elazab; Kannan R R Rengasamy; Natália Cruz-Martins; Helal F Hetta
Journal:  Front Med (Lausanne)       Date:  2021-04-14
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.